A double-blind, randomized, placebo-controlled, crossover trial of pentoxifylline for the prevention of chemotherapy-induced oral mucositis.

[1]  F. Appelbaum,et al.  A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation , 1993 .

[2]  C. Verdi.  Cancer Therapy and Oral Mucositis , 1993, Drug safety.

[3]  Norbertus C. Robben,et al.  The syndrome of 5‐fluorouracil cardiotoxicity. An elusive cardiopathy , 1993, Cancer.

[4]  G. Laurent,et al.  Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: a prospective, randomized trial. , 1993, Blood.

[5]  A. Zander,et al.  Pentoxifylline did not prevent transplant-related toxicity in 31 consecutive allogeneic bone marrow transplant recipients [letter; comment] , 1992 .

[6]  P. Soulié,et al.  Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  G. Donaldson,et al.  Clinical assessment scale for the rating of oral mucosal changes associated with bone marrow transplantation development of an oral mucositis index , 1992, Cancer.

[8]  U. Fuhr,et al.  Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro , 1992, Antimicrobial Agents and Chemotherapy.

[9]  G. Lyman,et al.  A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Singer,et al.  Phase I-II trial of pentoxifylline for the prevention of transplant- related toxicities following bone marrow transplantation [published erratum appears in Blood 1992 Jun 15;79(12):3397] [see comments] , 1991 .

[11]  W. Panje,et al.  Cisplatin and fluorouracil chemotherapy does not yield long-term benefit in locally advanced head and neck cancer: results from a single institution. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Edwards,et al.  Pentoxifylline inhibits interleukin-2-induced leukocyte-endothelial adherence and reduces systemic toxicity. , 1991, Surgery.

[13]  J. Nemunaitis,et al.  Phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor following allogeneic bone marrow transplantation. , 1991, Blood.

[14]  R. Wolfe,et al.  Kinin/prostaglandin system: its therapeutic value in surgical stress. , 1990, Critical care medicine.

[15]  Jiahuai Han,et al.  Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway , 1990, The Journal of experimental medicine.

[16]  D. Peterson,et al.  Pretreatment strategies for infection prevention in chemotherapy patients. , 1990, NCI monographs : a publication of the National Cancer Institute.

[17]  R. Strieter,et al.  Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxofylline , 1988 .

[18]  A. Berger,et al.  Development, testing, and application of the oral assessment guide. , 1988, Oncology nursing forum.

[19]  A. Fahr,et al.  Influence of pentoxifylline administered in vivo on the synthesis of PGI2 in human varicose veins. , 1988, Biomedica biochimica acta.

[20]  J. Jacobs,et al.  Photo-chemotherapy in advanced head and neck cancer , 1987 .

[21]  W. Fee,et al.  Chemotherapy as a substitute for surgery in the treatment of advanced resectable head and neck cancer. A report from the northern California oncology group , 1987, Cancer.

[22]  S. Clissold,et al.  Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. , 1987, Drugs.

[23]  H. Garewal,et al.  Neoadjuvant therapy for advanced head and neck cancer with allopurinol‐modulated high dose 5‐fluorouracil and cisplatin a phase I‐II study , 1987, Cancer.

[24]  F. Demard,et al.  Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck. , 1986, British Journal of Cancer.

[25]  Rosen Sw.  Oral complications of cancer chemotherapy--a review of 398 patients. , 1986 .

[26]  J. Jacobs,et al.  A randomized trial of cisplatin (CACP) + 5‐fluorouracil (5‐FU) infusion and CACP + 5‐FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck , 1985, Cancer.

[27]  S. Weitzman,et al.  Treatment of squamous-cell carcinoma of the head and neck with cisplatin and 5-fluorouracil. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  P. Citrin,et al.  A prospective evaluation of 5-fluorouracil plus cisplatin in advanced squamous-cell cancer of the head and neck. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  L. Gordon,et al.  Analysis of Complete Responders after Initial Treatment with Chemotherapy in Head and Neck Cancer , 1985, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[30]  J. Jacobs,et al.  Improved complete response rate and survival in advanced head and neck cancer after three‐course induction therapy with 120‐hour 5‐FU infusion and cisplatin , 1985, Cancer.

[31]  J. O'fallon,et al.  A phase II study of cis-diamminedichloroplatinum and 5-fluorouracil in advanced upper aerodigestive neoplasms. , 1984, Head & neck surgery.

[32]  Wheeley Ms,et al.  Indapamide in hypertension: a study in general practice of new or previously poorly controlled patients. , 1982 .

[33]  K. Schrör,et al.  The release of prostacyclin (PGI2) by pentoxifylline from human vascular tissue. , 1982, Arzneimittel-Forschung.